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Abstract
Thiazolidinediones, synthetic ligands of peroxisome proliferator-activated receptor Q (PPARQ), are reported to have direct
beneficial effects on diabetic nephropathy without lowering blood glucose levels in human and rat. We hypothesized these
effects of thiazolidinediones might be derived from PPARQ activation of kidney cells, and we examined the expression of
PPARQ and the effect of PPARQ agonists, troglitazone and 15-deoxy-N-prostaglandin J2 (15d-PGJ2), on the proliferation and
differentiation in rat mesangial cells. A single band of mRNA of PPARQ with a predicted size was detected in reverse
transcription-polymerase chain reaction products (RT-PCR) using established PCR probes of PPARQ. PPARQ protein in rat
mesangial cells was identified as PPARQ1 by a Western blot. In a gel mobility shift assay to determine a binding activity of
PPARQ, the nuclear protein from rat mesangial cells bound to a 32P-labeled oligonucleotide probe, including PPAR response
elements. A synthetic and a natural ligand of PPARQ, troglitazone and 15d-PGJ2, decreased thymidine incorporation in a
dose dependent manner. After 7 days incubation with troglitazone and 15d-PGJ2, K-smooth muscle actin expression, a
marker of mesangial cell de-differentiation, was decreased significantly compared to that of control. These results indicate
that PPARQ1 is expressing in rat mesangial cells, and PPARQ1 activation with its agonists modulates the proliferation and
differentiation of cultured rat mesangial cells. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Peroxisome proliferator-activated receptors
(PPARs) are a family of ligand-activated nuclear re-
ceptor transcriptional factors, and have three mem-
bers (K, N and Q). PPARs form heterodimers with
retinoic X receptor bind to PPAR response elements
(PPRE) in the promoter region of speci¢c target
genes to regulate their expressions [1,2]. PPARs
play important roles in the lipid and glucose metab-
olisms and the di¡erentiation of adipocytes [3,4]. Re-
cently, the expressions of PPARQ in macrophages
and vascular smooth muscle cells other than adipo-
cytes are also reported, and seem to play important
roles in the pathogenesis of atherosclerosis by regu-
lating activation of de-di¡erentiation of the cells [5^
9].
We reported that troglitazone, one of the thiazoli-
dinediones which are speci¢c synthetic ligands for
PPARQ, improved intracellular glucose metabolism
under a high glucose condition in rat mesangial cells,
in spite of the presence of increased glucose uptake
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with an upregulation of facilitated glucose transport-
er 1 by the cells [10]. These ¢ndings raised a possi-
bility of the presence of PPARQ in rat mesangial
cells, and its presence may be associated with some
renal diseases. Since the activation and phenotypic
change in mesangial cells are considered as the fea-
tures of mesangial proliferative glomerulonephritis
[11] and diabetic nephropathy [12], PPARQ in mesan-
gial cells may play important roles in pathogenesis of
nephropathy. In the present study, we examined the
expression of PPARQ and the e¡ect of agonists of
PPARQ on the proliferation and di¡erentiation in
rat mesangial cells.
2. Materials and methods
2.1. Isolation and culture of rat mesangial cells
Mesangial cells were isolated from kidneys of
4-week-old Sprague^Dawley rats by a di¡erential siev-
ing procedure as previously reported [10], and were
cultured in plastic plates (NUNC Brand Products,
Denmark) in a 1:1 mixture of Dulbecco’s modi¢ed
Eagles’s medium (DMEM) and Ham’s F-12 (both
from Sigma, St. Louis, MO) containing 10% FBS
(Gibco BRL, Grand island, NY), 10% Nu-serum
(Collaborative Research, Bedford, MA), penicillin
(100 U/ml) and streptomycin (100 Wg/ml) (Sigma).
After having reached over 90% con£uency, mesangial
cells from 5^9 passages were used for the following
experiments.
2.2. Reverse transcription-polymerase chain reaction
(RT-PCR)
Total RNA of rat mesangial cells was prepared
using Isogen (Wako Junyaku, Osaka, Japan). To am-
plify a 386-base pair of cDNA fragment, the sequen-
ces of PCR primers for PPARQ : forward (5P-
AACCGGAACAAATGCCAGTA-3P) and reverse
(5P-TGGCAGCAGTGGAAGAATCG-3P) were syn-
thesized and the RT-PCR was carried out as re-
ported previously [5]. In brief, 2 Wg of total RNA
of rat mesangial cells was reverse-transcribed to
cDNA with a reverse transcriptase (Promega, Madi-
son, WI) at 37‡C for 1 h in a standard bu¡er. The
PCR reaction was carried out in the standard bu¡er
with 0.5 WM of each primer, 1.5 mM MgCl2 and 0.5
U Taq polymerase (Toyobo, Osaka, Japan). The
temperature program for the ampli¢cation was 35
cycles of 30 s at 94‡C, 30 s at 54‡C and 1 min at
72‡C.
2.3. Western blot of PPARQ
For the Western blot of PPARQ, rat mesangial
cells were harvested and lysed in a solution contain-
ing 20 mM Tris/HCl, 150 mM NaCl, 1 mM EDTA,
1 mM DTT, 1 mM PMSF, 1% Nonidet P-40 and 1%
Triton X following a modi¢ed method of a previous
report [13]. Protein extracts were obtained by centri-
fugation of the lysate. The protein extract (50 Wg)
and positive controls of PPARQ1 and PPARQ2 pro-
tein were separated on 10% non-gradient acryl amide
gel using sodium dodecyl sulfate acryl amide gel elec-
trophoresis (SDS-PAGE), and were transferred to
nitrocellulose sheets. Rabbit IgG antibody against
PPARQ (Santa Cruz Biotechnology, California) was
reacted (1:1000 dilution), followed by peroxidase
linked protein A (Amersham). Immunoreactive
bands were visualized by Western blotting detection
ECL reagents (Amersham) with the use of X-Omatic
AR ¢lm (Eastman-Kodak, Rochester, NY). Jurkat
whole cell lysate (Santa Cruz Biotechnology) was
used for a positive control of PPARQ1 protein, and
PPARQ2 protein was kindly gifted from Dr. Jiro Ma-
sugi [13].
2.4. Gel mobility shift assay
To obtain nuclear extracts from rat mesangial
cells, the cells were lysed in 10 mM HEPES (pH
7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA,
0.5 mM PMSF, 1 mM DTT and 0.5% NP-40. Nuclei
obtained after centrifugation at 13 000Ug for 30 s
were lysed in 20 mM HEPES (pH 7.9), 0.4 M
NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF,
and 1 mM DTT. After centrifugation at 13 000Ug
for 5 min, the supernatant was used for gel mobility
shift assay. A double-stranded 23-bp oligonucleotide
probe (5P-GGACCAGGACAAAGGTCACGTTC-
3P), synthesized according to the sequence of rat
acyl-CoA oxidase was labeled with 32P-ATP (Amer-
sham Life Science, Buckinghamshire, UK) [5]. A typ-
ical binding reaction mixture, contained oligonucleo-
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tide probes and 5 Wg of the nuclear extract in a ¢nal
volume of 25 Wl, was incubated at room temperature
for 20 min, and analyzed by 5% polyacrylamide gel
electrophoresis. The autoradiograph of the dried gel
was determined by BAS 2000 system (Fuji ¢lm, To-
kyo, Japan). To characterize speci¢c DNA binding
proteins, we incubated nuclear extracts with a specif-
ic antibody for PPARQ for 12 h at 4‡C before the
addition of the probe. The speci¢c antibody used in
Gel mobility shift assay was kindly gifted by Dr. Jiro
Masugi [13].
2.5. Thymidine incorporation
For determination of thymidine incorporation, the
mesangial cells were preincubated for 24 h in
DMEM-F12 containing 1% FCS and 1% Nu-serum
in 12-well plates (28 mm diameter, Nunc) with vari-
ous concentrations of 15d-PGJ2 and troglitazone,
and washed three times with phosphate-bu¡ered sa-
line (PBS). Then the cells were incubated with 2 WCi/
ml of 3H-thymidine for 6 h, the cells were solubilized
with 500 Wl of 0.5 M NaOH after washing with ice-
cold PBS. The cellular radioactivities were counted
after neutralization with 2 M acetic acid, using Aloka
Liquid Scintillation Counter LSC 1000 (Aloka, To-
kyo, Japan). Thymidine incorporation was expressed
as per mg of cell protein.
2.6. Determination of K-smooth muscle actin
expression
Mesangial cells in 100 mm plates were incubated
for 7 days in 10 ml DMEM^F12, 1% FCS, 1% Nu-
serum, and 5 mM of glucose, in the presence or
absence of troglitazone (4.5 WM) and 15d-PGJ2
(2.5 WM), changing media every 2 days. The cells
were harvested in a sodium dodecyl sulfate lysis bu¡-
er, then the cell lysate was sonicated and boiled.
After centrifugation at 12 000Ug for 15 min at
4‡C, the supernatant was used to determine
K-smooth muscle actin expression by Western blots.
The samples corresponding to 300 ng of the DNA
contents of the same plates were separated on 10%
non-gradient acryl amide gel using SDS^PAGE.
Antibody against K-smooth muscle actin (Sigma)
was reacted (1:1000 dilution), followed by peroxi-
dase-linked protein A (Amersham).
2.7. Other determinations
Densitometric analyses were conducted by NIH
image program. DNA contents were determined by
the Hoechst 33258 dye (Sigma) method using a TKO
100 Spectrophotometer (Hoe¡er Scienti¢c Instru-
ments, San Francisco, CA). Protein concentration
was measured by the Coomassie brilliant blue meth-
od using a Bio-Rad protein assay kit (Bio-Rad) and
bovine serum albumin as a standard.
2.8. Statistical analysis
Data are expressed as mean þ S.E.M. Analysis of
variance (ANOVA) and Student’s t-test (two-tailed)
were used for statistical determinations; a level of
P6 0.05 was considered statistically signi¢cant.
3. Results
3.1. Expression of PPARQ mRNA and protein
The RT-PCR products from total mRNA of rat
mesangial cells analyzed by electrophoresis with ethi-
dium bromide in 1.4% agarose gel are shown in Fig.
1. A single band with a predicted size (386 bp: in-
dicated by an arrow) was detected in RT-PCR prod-
ucts, which demonstrates PPARQ mRNA expression
(lane 1). The same RT-PCR reactions without re-
Fig. 1. Expression of mRNA of PPARQ in rat mesangial cell by
the RT-PCR. A single band with predicted size (386 bp: indi-
cated by an arrow) of PPARQ DNA was detected in lane 1.
The same RT-PCR reaction, without reverse transcription (lane
2), did not make any PCR products.
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verse transcription (lane 2) did not make any PCR
products.
Western blot analysis revealed that the rabbit
PPARQ antibody reacts with both PPARQ1 (55
kDa) and PPARQ2 protein (60 kDa) (Fig. 2), PPARQ
protein expressed in rat mesangial cells was identi¢ed
to have the same reaction with PPARQ1.
3.2. Binding of nuclear proteins from rat mesangial
cells to PPRE oligonucleotide
As shown in Fig. 3, the addition of nuclear ex-
tracts resulted in a retarded thick band (indicated
by thick arrow) consistently (lane 1). This band
was abolished by a 100-fold molar excess of unla-
beled PPRE oligonucleotide (lane 2). Incubation of
nuclear extracts with a speci¢c antibody for PPARQ
prior to the reaction produced a supershifted band
(lane 3), indicating that PPARQ was the component
of this DNA^protein complex.
3.3. E¡ect of PPARQ agonists on proliferation and
di¡erentiation of rat mesangial cells
The e¡ects of troglitazone and 15d-PGJ2 on thy-
midine incorporation by rat mesangial cells are
shown in Fig. 4. Both troglitazone (Fig. 4A) and
15d-PGJ2 (Fig. 4B) decreased 3H-thymidine incorpo-
ration in a dose-dependent manner. The concentra-
tion of troglitazone was chosen to 0.23, 0.45, 2.3, 4.5,
Fig. 2. Expression of PPARQ protein in rat mesangial cells by
Western blot analysis. Cell lysates of rat mesangial cells were
observed in a single band at a molecular weight of 55 kDa.
The identity of PPARQ band was con¢rmed by comigration
with the band seen in PPARQ1 from Jurkat cell. PPARQ2 pro-
tein was observed a single band at 60 kDa.
Fig. 3. Detection of binding of nuclear proteins from rat me-
sangial cell and PPARQ protein to PPRE oligonucleotide using
gel mobility shift assay. 32P-labeled PPRE oligonucleotide probe
and protein complex was shown as a thick band in lane 1. This
band was abolished by excess of unlabeled PPRE oligonucleo-
tide (lane 2). Incubation of nuclear extracts with a speci¢c anti-
body for PPARQ prior to the reaction produced a supershifted
band (lane 3). The PPARQ protein exhibited the same band ob-
served in lane 1 (lane 4).
Fig. 4. E¡ect of troglitazone (A) and 15d-PGJ2 (B) on thymi-
dine incorporation in rat mesangial cells. Mesangial cells were
preincubated for 24 h in DMEM-F12 containing 1% FCS and
1% Nu-serum with various concentrations of 15d-PGJ2 and tro-
glitazone. Cellular radioactivities of 3H-thymidine after the in-
cubation with 2 WCi/ml of 3H-thymidine for 6 h were expressed
as relative to those of control cells. Data are mean þ S.E.M.,
n = 4 in each condition. **P6 0.01 vs. control. ****P6 0.001
vs. control.
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23 WM, corresponding to 0.1, 0.2, 1, 2, 10 Wg/ml.
Troglitazone of more than 2.3 WM and 15d-PGJ2
of more than 2.5 WM signi¢cantly decreased 3H-thy-
midine incorporation.
The expression of K-smooth muscle actin after
7 days incubation with 4.5 WM of troglitazone
was signi¢cantly decreased compared to that of
control (Fig. 5A,B). Its expression did not change
after 3 and 5 days incubation with troglitazone
(Data not shown). 15d-PGJ2 of 2.5 WM also de-
creased K-smooth muscle actin after 7 days incuba-
tion (Fig. 5C).
4. Discussion
PPARQ has been reported to have three isoforms,
PPARQ1, Q2 and Q3, which have speci¢c and distinc-
tive expression patterns in human [14]. PPARQ1 and
Q3 rise to an identical protein and Q2 protein has
additional amino acids in human. In the present
study, we demonstrated the expression of mRNA
of PPARQ by RT-PCR and PPARQ1 protein by
Western blot in rat mesangial cells. These results
may support the previous report that only PPARQ1
expression was observed in human kidney [15]. We
also showed the protein in the nuclear extracts from
rat mesangial cells bound to PPRE. These data sug-
gest that PPARQ1 is functionally expressed in rat
mesangial cells.
The K-smooth muscle actin is considered as a phe-
notypic marker of activated and de-di¡erentiated me-
sangial cells [16]. The increase of K-smooth muscle
actin is reported in mesangial proliferative glomeru-
lonephritis [11] and diabetic nephropathy [12]. A
strong expression of K-smooth muscle actin of me-
sangial cells by a two-dimensional culture is sup-
pressed with the cell di¡erentiation of the cells by a
three-dimensional culture that is more near to phys-
iological conditions [17].
Troglitazone (one of thiazolidinediones) and 15d-
PGJ2 (one of metabolites of prostaglandin J2) are a
synthetic ligand and a natural ligand for PPARQ,
respectively. In this study, the suppressive e¡ects of
troglitazone and 15d-PGJ2 on the thymidine incor-
poration and production of K-smooth muscle actin
by rat mesangial cells were observed, which indicate
that PPARQ agonists suppress the cellular prolifera-
tion and de-di¡erentiation of rat mesangial cells. The
regulation of phenotypic changes by PPARQ is re-
ported in smooth muscle cells and macrophages
[6,9]. Since the doses of PPARQ agonists in this study
seem to be high enough to upregulate transcriptional
activity of PPARQ [18,19], we think the e¡ect of
PPARQ agonists on the mesangial cells in this study
depends on PPARQ pathway.
PPARQ agonists are reported to have some addi-
tional e¡ects independent of PPARQ such as an up-
Fig. 5. The e¡ect of troglitazone on K-smooth muscle actin ex-
pression in rat mesangial cells. Mesangial cells on 100 mm
plates were incubated for 7 days in 10 ml DMEM-F12, 1%
FCS, 1% Nu-serum, and 5 mM of glucose, in the presence or
absence of 4.5 WM troglitazone. (A) Western blot of K-smooth
muscle actin. K-Smooth muscle actin was observed as a band at
42 kDa. (B) Relative density of K-smooth muscle actin. The cell
lysate corresponding to 300 ng of DNA contents were analyzed
by Western blot. Data are mean þ S.E.M. n = 4 in each condi-
tion. **P6 0.01 vs. control. (C) Comparison of e¡ect of 2.5
WM 15d-PGJ2 and 4.5 WM troglitazone on K-smooth muscle ac-
tin expression in rat mesangial cells.
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regulation of NO synthesis [20,21]. The distributions
of PPARs were reported in many tissues, and the
presence of PPARK, N and Q were reported in the
rat glomerulus [22]. Although we did not examine
PPARK and N other than PPARQ in rat mesangial
cells, these PPARs may have some e¡ects on prolif-
eration and di¡erentiation of the cells, since PPARK
activation is also reported to have an anti-atheroge-
netic e¡ect in human smooth muscle cells [23]. Fur-
ther experiments concerning PPARQ signaling and
PPAR isoforms in mesangial cells are needed to clar-
ify the e¡ects of PPARs on the cells.
Mesangial cells play important roles in the pro-
gression of some kinds of renal disease including
diabetic nephropathy, since over-production of type
IV and type VI collagen by mesangial cells seem to
be important to form the basement membrane thick-
ening and mesangial expansion [24]. Recently, thia-
zolidinediones are reported to inhibit progression of
diabetic nephropathy in rat and human without low-
ering glucose levels [25,26]. Phenotypic modulation
of mesangial cells by an activation of PPARQ with
thiazolidinediones treatment may be an additional
bene¢cial e¡ect on diabetic nephropathy, and may
have some e¡ect on other kidney diseases.
In conclusion, PPARQ1 is expressed in cultured rat
mesangial cells, and PPARQ agonists modulates pro-
liferation and di¡erentiation of rat mesangial cells.
References
[1] I. Issemann, S. Green, Activation of a member of the steroid
hormone receptor superfamily by peroxisome proliferations,
Nature 347 (1990) 645^650.
[2] H. Keller, C. Dreyer, J. Medin, A. Mahfoudi, K. Ozato, W.
Wahli, Fatty acids and retinoids control lipid metabolism
through activation of peroxisome proliferator-activated re-
ceptor-retinoid X receptor heterodimers, Proc. Natl. Acad.
Sci. USA 90 (1993) 2160^2164.
[3] H. Keller, A. Mahfoudi, C. Dreyer, A.K. Hihi, J. Medin, K.
Ozato, W. Wahli, Peroxisome proliferator-activated recep-
tors and lipid metabolism, Ann. New York Acad. Sci. 684
(1993) 157^173.
[4] A. Chawla, E.J. Schwarz, D.D. Dimaculangan, M.A. Lazar,
Peroxisome proliferator-activated receptor (PPAR) Q : adi-
pose-predominant expression and induction early in adipo-
cyte di¡erentiation, Endocrinology 135 (1994) 798^800.
[5] K. Iijima, M. Yoshizumi, J. Ako, M. Eto, S. Kim, M. Ha-
shimoto, N. Sugimoto, Y.Q. Liang, N. Sudoh, K. Toba, Y.
Ouchi, Expression of peroxisome proliferator-activated re-
ceptor gamma (PPARQ) in rat aortic smooth muscle cells,
Biochem. Biophys. Res. Commun. 247 (1998) 353^356.
[6] M. Ricote, A.C. Li, T.M. Willson, C.J. Kelly, C.K. Glass,
The peroxisome proliferator-activated receptor-Q is a nega-
tive regulator of macrophage activation, Nature 391 (1998)
79^82.
[7] N. Marx, G. Sukhova, C. Murphy, P. Libby, J. Plutzky,
Macrophages in human atheroma contain PPARQ : di¡eren-
tiation-dependent peroxisomal proliferator-activated recep-
tor Q (PPARQ) expression and reduction of MMP-9 activity
through PPARQ activation in mononuclear phagocytes in
vitro, Am. J. Pathol. 153 (1998) 17^23.
[8] R.E. Law, W.P. Meehan, X.P. Xi, K. Graf, D.A. Wuthrich,
W. Coats, D. Faxon, W.A. Hsueh, Troglitazone inhibits
vascular smooth muscle cell growth and intimal hyperplasia,
J. Clin. Invest. 98 (1996) 1897^1905.
[9] E. Morikang, S.C. Benson, T.W. Kurtz, H.A. Pershadsingh,
E¡ects of thiazolidinediones on growth and di¡erentiation of
human aorta and coronary myocytes, Am. J. Hypertens. 10
(1997) 440^446.
[10] T. Asano, M. Wakisaka, M. Yoshinari, S. Nakamura, Y.
Doi, M. Fujishima, Troglitazone enhances glycolysis and
improves intracellular glucose metabolism in rat mesangial
cells, Metabolism, in press.
[11] R.J. Johnson, H. Iida, C.E. Alpers, M.W. Majesky, S.M.
Schwartz, P. Pritzi, K. Gordon, A.M. Gown, Expression
of smooth muscle cell phenotype by rat mesangial cells in
immune complex nephritis. Alpha-smooth muscle actin is a
marker of mesangial cell proliferation, J. Clin. Invest. 87
(1991) 847^858.
[12] H. Makino, N. Kashihara, H. Sugiyama, K. Kanao, T. Se-
kikawa, K. Okamoto, Y. Maeshima, Z. Ota, R. Nagai, Phe-
notypic modulation of the mesangium re£ected by contrac-
tile proteins in diabetes, Diabetes 45 (1995) 488^495.
[13] J. Masugi, Y. Tamori, M. Kasuga, Inhibition of adipogene-
sis by a COOH-terminary truncated mutant of PPARQ2 in
3T3-L1 cells, Biochem. Biophys. Res. Commun. 264 (1999)
93^99.
[14] J. Auwerx, PPARQ the ultimate thrifty gene, Diabetologia 42
(1999) 1033^1049.
[15] L. Fajas, D. Auboef, E. Raspe, K. Schoonjans, A.-M. Le-
febvre, R. Saladin, J. Najib, M. Laville, J.-C. Fruchart, S.
Deeb, A. Vidal-Puig, J. Flier, M.R. Briggs, B. Steals, H.
Vidal, J. Auwerx, The organization, promoter analysis, and
expression of the human PPARQ gene, J. Biol. Chem. 272
(1997) 18779^18789.
[16] R.J. Johnson, J. Floege, A. Yoshimura, H. Iida, W.G. Cous-
er, C.E. Alpers, The activated mesangial cell : a glomerular
‘myo¢broblast’?, J. Am. Soc. Nephrol. 2 (1992) S190^197.
[17] M. Kitamura, T. Mitarai, R. Nagasawa, N. Maruyama, Dif-
ferentiated phenotype of glomerular mesangial cells in nod-
ular culture, Am. J. Physiol. 270 (1996) F614^622.
[18] J. Berger, P. Bailey, C. Biswas, C.A. Cullinan, T.W. Doeb-
ber, N.S. Hayes, R. Saperstein, R.G. Smith, M.D. Leibo-
witz, Thiazolidinediones produce a conformational change
BBAMCR 14641 22-5-00
T. Asano et al. / Biochimica et Biophysica Acta 1497 (2000) 148^154 153
in peroxisomal proliferator-activated receptor-gamma: bind-
ing and activation correlate with antidiabetic actions in db/
db mice, Endocrinology 137 (1996) 354^366.
[19] S.A. Kliewer, J.M. Lenhard, T.M. Willson, I. Patel, D.C.
Morris, J.M. Lehmann, A prostaglandin J2 metabolite binds
peroxisome proliferator-activated receptor gamma and pro-
motes adipocyte di¡erentiation (PPARQ), Cell 83 (1995) 813^
819.
[20] Y. Hattori, S. Hattori, K. Kasai, Troglitazone upregulates
nitric oxide synthesis in vascular smooth muscle cells, Hyper-
tension 33 (1999) 943^948.
[21] T.V. Petrova, K.T. Akama, L.J. Van Elkdik, Cyclopente-
none prostaglandins suppress activation of microglia:
down regulation of inducible nitric-oxide synthase by 15-de-
oxy-v12;14-prostaglandin J2, Proc. Natl. Acad. Sci. USA 96
(1999) 4668^4673.
[22] O. Braissant, B. Desvergne, Di¡erential expression of perox-
isome proliferator-activated receptors (PPARs): tissue distri-
bution of PPAR-K, -L and -Q in the adult rat, Endocrinology
137 (1995) 354^366.
[23] B. Staels, W. Koenig, A. Habib, R. Merval, M. Lebret, I.P.
Torra, P. Delerive, A. Fade, G. Chinetti, J.C. Fruchart, J.
Najib, J. Maclouf, A. Tedgui, Activation of human aortic
smooth-muscle cells is inhibited by PPARK but not by PPARQ
activators, Nature 393 (1998) 790^793.
[24] M. Wakisaka, M.J. Spiro, R.G. Spiro, Synthesis of type IV
collagen by cultured glomerular cells and comparison of its
regulation by glucose and other factors with that of type IV
collagen, Diabetes 43 (1994) 95^103.
[25] M. Fujii, R. Takemura, M. Yamaguchi, G. Hasegawa, H.
Shigeta, K. Nakano, M. Kondo, Troglitazone (CS-045)
ameliorates albuminuria in streptozotocin-induced diabetic
rats, Metabolism 46 (1997) 981^983.
[26] E. Imano, T. Kanda, Y. Nakatani, T. Nishida, K. Arai, M.
Motomura, Y. Kajimoto, Y. Yamasaki, M. Hori, E¡ect of
troglitazone on microalbuminuria in patients with incipient
diabetic nephropathy, Diabetes Care 21 (1998) 2135^
2139.
BBAMCR 14641 22-5-00
T. Asano et al. / Biochimica et Biophysica Acta 1497 (2000) 148^154154
